[go: up one dir, main page]

CL2019002314A1 - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). - Google Patents

Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).

Info

Publication number
CL2019002314A1
CL2019002314A1 CL2019002314A CL2019002314A CL2019002314A1 CL 2019002314 A1 CL2019002314 A1 CL 2019002314A1 CL 2019002314 A CL2019002314 A CL 2019002314A CL 2019002314 A CL2019002314 A CL 2019002314A CL 2019002314 A1 CL2019002314 A1 CL 2019002314A1
Authority
CL
Chile
Prior art keywords
ahr
aryl hydrocarbon
hydrocarbon receptor
modulating compounds
compounds
Prior art date
Application number
CL2019002314A
Other languages
English (en)
Inventor
Christoph Steeneck
Michael Albers
Thomas Hoffmann
Uirich Deuschle
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of CL2019002314A1 publication Critical patent/CL2019002314A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS QUE PUEDEN ACTUAR COMO MODULADORES DEL RECEPTOR DE HIDROCARBUROS DE ARILO (AHR) Y, EN PARTICULAR, COMO ANTAGONISTAS DE AHR. LA INVENCIÓN ADEMÁS SE REFIERE AL USO DE LOS COMPUESTOS PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES Y/O CONDICIONES A TRAVÉS DE LA UNIÓN DE DICHO RECEPTOR DE HIDROCARBUROS DE ARILO POR DICHOS COMPUESTOS.
CL2019002314A 2017-02-21 2019-08-16 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). CL2019002314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17000276 2017-02-21

Publications (1)

Publication Number Publication Date
CL2019002314A1 true CL2019002314A1 (es) 2019-12-20

Family

ID=58108394

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002314A CL2019002314A1 (es) 2017-02-21 2019-08-16 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).

Country Status (18)

Country Link
US (1) US20200031805A1 (es)
EP (1) EP3585780A1 (es)
JP (1) JP2020508311A (es)
KR (1) KR20190120293A (es)
CN (1) CN110325532A (es)
AR (1) AR110990A1 (es)
AU (1) AU2018224166A1 (es)
BR (1) BR112019015720A2 (es)
CA (1) CA3051645A1 (es)
CL (1) CL2019002314A1 (es)
EA (1) EA201991598A1 (es)
IL (1) IL268300A (es)
MA (1) MA47585A (es)
MX (1) MX2019009836A (es)
PH (1) PH12019550155A1 (es)
TW (1) TW201835070A (es)
UY (1) UY37610A (es)
WO (1) WO2018153893A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201925194A (zh) 2017-11-20 2019-07-01 美商雅里俊公司 吲哚化合物及其用途
FI3749669T6 (fi) 2018-02-06 2024-11-13 Ideaya Biosciences Inc AHR-modulaattoreita
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
WO2020043880A1 (en) * 2018-08-31 2020-03-05 Jaguahr Therapeutics Pte Ltd Heterocyclic compounds as ahr modulators
AU2020258394A1 (en) 2019-04-15 2021-10-28 Ariagen, Inc. Chiral indole compounds and their use
EP4093739A1 (en) * 2020-01-23 2022-11-30 Phenex Pharmaceuticals AG Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN115215720B (zh) * 2021-04-19 2023-08-22 中国科学院化学研究所 含薁单元的石墨烯纳米片段分子—薁并玉红省及其合成方法与应用
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用
CN115093400B (zh) * 2021-09-18 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂及其用途和制备方法
WO2023088435A1 (zh) * 2021-11-19 2023-05-25 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
KR20250073623A (ko) 2022-10-03 2025-05-27 재규어 테라퓨틱스 피티이 리미티드 AhR 신호전달의 조절에 유용한 화합물
AR133526A1 (es) * 2023-08-09 2025-10-08 Daewoong Pharmaceutical Co Ltd Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
CN117447402A (zh) * 2023-10-18 2024-01-26 德明药泰生物技术（深圳）有限公司 芳香烃受体调节剂类化合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002500A1 (fr) * 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. Derive de 2-phenylindole
AU2003270426A1 (en) * 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
PT2488486T (pt) * 2009-10-13 2019-11-05 Ligand Pharm Inc Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos
AU2011282776B2 (en) 2010-07-27 2014-06-12 Boston Medical Center Corporation Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
EP2909172A1 (en) * 2012-10-17 2015-08-26 F. Hoffmann-La Roche AG 6-aminoindole derivatives as trp channel antagonists

Also Published As

Publication number Publication date
CA3051645A1 (en) 2018-08-30
EP3585780A1 (en) 2020-01-01
BR112019015720A2 (pt) 2020-03-24
EA201991598A1 (ru) 2020-03-10
IL268300A (en) 2019-09-26
UY37610A (es) 2018-03-23
AU2018224166A1 (en) 2019-08-01
JP2020508311A (ja) 2020-03-19
US20200031805A1 (en) 2020-01-30
WO2018153893A1 (en) 2018-08-30
TW201835070A (zh) 2018-10-01
MA47585A (fr) 2020-01-01
AR110990A1 (es) 2019-05-22
MX2019009836A (es) 2019-10-04
PH12019550155A1 (en) 2020-03-16
CN110325532A (zh) 2019-10-11
KR20190120293A (ko) 2019-10-23

Similar Documents

Publication Publication Date Title
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2019002108A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2019002112A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2019003015A1 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CL2018002467A1 (es) El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint
CL2020000375A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
MX2017014375A (es) Moduladores del ccr2.
CL2016000341A1 (es) Métodos para tratar la miositis por cuerpos de inclusión esporádica
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
UY35993A (es) Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
SV2018005731A (es) Piperidinas sustituidas con halo como moduladores del receptor de orexina
ECSP16074207A (es) Pirazinas moduladoras de gpr6
MX2020006355A (es) Pirrolidinamidas ii sustituidas.